Acquired alterations in CRBN and CUL4B due to iMiD therapies not only have relevance to MM treatment but also presage analogous mutations that are likely to be acquired based on various proteolysis targeting chimera (PROTAC) therapies under development48. The gene discussed is CRBN; the disease is Miyoshi myopathy.